Literature DB >> 32395850

Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations.

Rachel M Deacon1,2,3, Kristie Mammen2,3, Jennifer Holmes3,4, Adrian Dunlop3,5,6, Raimondo Bruno7,8, Llewellyn Mills1,2,3, Robert Graham3,9,10, Nicholas Lintzeris1,2,3.   

Abstract

INTRODUCTION AND AIMS: The Australian Treatment Outcomes Profile (ATOP) is a brief clinical tool measuring recent substance use, health and wellbeing among clients attending alcohol and other drug (AOD) treatment services. It has previously been assessed for concurrent validity and inter-rater reliability. In this study we examine whether it is suitable for administration over the telephone. DESIGN AND METHODS: We recruited a sample of 107 AOD clients across public sector specialist AOD treatment services in New South Wales, Australia between 2016 and 2018. Participants had a mean age of 47 years and 46% were female. Participants completed a face-to-face ATOP and a phone ATOP with a researcher within 5 days. Comparisons between the two administration modes were undertaken using Spearman's rank correlation coefficient for continuous or ordinal variables, and Cohen's Kappa for nominal variables.
RESULTS: Among 107 participants, 59% were attending for alcohol treatment and 41% for opioid treatment. Most ATOP items (76%) reached above 0.7 (good) or 0.9 (excellent) agreement between face-to-face and telephone use. DISCUSSION AND
CONCLUSIONS: Our findings suggest that the ATOP is a suitable instrument for telephone monitoring of recent substance use, health and social functioning among AOD clients. Its validation for remote use over the telephone will support staff to monitor clients' risks and outcomes-of particular relevance in response to the COVID-19 pandemic in which services are increasingly relying on telework approaches to client monitoring.
© 2020 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Keywords:  health care; outcome assessment; psychometric; substance-related disorder; telemedicine

Mesh:

Year:  2020        PMID: 32395850     DOI: 10.1111/dar.13088

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  3 in total

1.  Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia.

Authors:  Nicholas Lintzeris; Rachel M Deacon; Victoria Hayes; Tracy Cowan; Llewellyn Mills; Laila Parvaresh; Lucy Harvey Dodds; Louisa Jansen; Raelene Dojcinovic; Man Cho Leung; Apo Demirkol; Therese Finch; Kristie Mammen
Journal:  Drug Alcohol Rev       Date:  2021-09-14

2.  Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder.

Authors:  Allison M Gustavson; Adam J Gordon; Marie E Kenny; Haley McHenry; Julie Gronek; Princess E Ackland; Hildi J Hagedorn
Journal:  Subst Abus       Date:  2020-09-16       Impact factor: 3.716

3.  Digital Interventions to Save Lives From the Opioid Crisis Prior and During the SARS COVID-19 Pandemic: A Scoping Review of Australian and Canadian Experiences.

Authors:  Andrea Donnell; Chandana Unnithan; Jessica Tyndall; Fahad Hanna
Journal:  Front Public Health       Date:  2022-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.